SAN DIEGO, CA / ACCESS Newswire / January 31, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf ...

NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - January 31, 2025) - Novo Nordisk A/S (NYSE: ...

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

Shares of newly public Metsera (MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Read more here.

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Donald Trump has on several occasions floated the idea of buying Greenland, the autonomous Danish territory. However, there is no shortage of economic leverage for Denmark to hurt the United States.

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...